AstraZeneca collaborates on cancer nanomedicine

04/22/2013 | PharmaTimes (U.K.)

AstraZeneca and Bind Therapeutics will collaborate on a targeted, programmable, nanotechnology cancer treatment involving a kinase inhibitor. The nanoparticles, which Bind calls Accurins, selectively accumulate, causing higher drug concentrations at the site of a tumor while sparing healthy tissue. AstraZeneca is also working with Horizon Discovery on a kinase therapy that targets the K-Ras mutation in various cancers, including of the lung and colon.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Claims Director
PacificSource
Springfield, OR
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA